Clintrak Pharmaceutical Services, LLC (CPS) Signs Lease for its Freiburg, Germany Facility and Establishes Clintrak Pharmaceutical Services GmbH as its European Base of Operation
CPS is pleased to announce that it has agreed to terms and signed the lease for its new facility in Freiburg, Germany.
23 May 2005 -- Freiburg, Germany: CPS is pleased to announce that it has agreed to terms and signed the lease for its new facility in Freiburg, Germany. The state-of-the-art facility is approximately 3,500 m2 (35,000 ft. 2) and will require minor modifications to become fully operational as the company's Clinical Trial Material (CTM) Packaging and Logistics center in Europe. The company will also be housing its European label reprinting capability from this site which will allow it to provide reprints of all labels including its flagship GlobalPly Booklet Labels. CPS anticipates that the facility will be available for audits by 1 August 2005. The new facility will be known as CPS GmbH.
In addition to the facility, the third version of the company's proprietary Clinical Trial Material Software (CTMS) will be completed and validated. CTMS 3.0 will encompass all requirements for the German facility as well as additional functionality for on-going operations. The software, which is compliant with 21 CFR Part 11, will manage all areas of the company's operation and provides seamless data for the company's clients. Brian Jusas, CEO, stated "the ability to utilize CTMS for all activities within our CTM operations, at both sites, is critical in providing clean, real-time data that has not been transferred or manipulated prior to provision to our clients."
Philippe Muller, who has joined the organization as Director, Qualified Person is very excited with the new facility stating "the acquisition of this facility will allow CPS to move rapidly to service the needs of the CTM industry throughout Europe".
CPS is a privately held company which provides CTM Label and Logistics solutions to Pharmaceutical and Biotechnology industry.
For more information, please contact Charles J. Gettis, Vice President, Corporate Development at cgettis@acculogix-usa.com or +215.826.8002 or Philippe Muller, Director, Qualified Person at +49 76150380.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
